• Russell 2000 (June 2016)

Novavax, Inc.

GAITHERSBURG, MD, 20878-1760  United States
(240) 268-2000
Company Type: Public Parent

Out to ax the dreaded flu is Novavax, a producer of novel, next-generation vaccines designed to prevent life-threatening infectious diseases, such as the influenza virus. The clinical-stage company uses its own virus-like particle (VLP) technology that, unlike traditional vaccines which are grown in chicken eggs, use recombinant proteins grown from insect cell lines. Its manufacturing process is also faster and more flexible than traditional manufacturing methods -- a fact that might help the vaccines succeed in combating fast-changing strains of pandemic influenza. Candidates in the company's pipeline include vaccines for seasonal and pandemic influenza, Respiratory Syncytial virus (RSV), Varicella Zoster (shingles), and HIV.

Try D&B Hoovers Free

Financial Statements